Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]

Detalles Bibliográficos
Autores principales: Hernandez, Nancy E., Jankowski, Wojciech, Frick, Rahel, Kelow, Simon P., Lubin, Joseph H., Simhadri, Vijaya, Adolf-Bryfogle, Jared, Khare, Sagar D., Dunbrack, Roland L., Gray, Jeffrey J., Sauna, Zuben E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493423/
https://www.ncbi.nlm.nih.gov/pubmed/37701412
http://dx.doi.org/10.1016/j.heliyon.2023.e17901
_version_ 1785104471938826240
author Hernandez, Nancy E.
Jankowski, Wojciech
Frick, Rahel
Kelow, Simon P.
Lubin, Joseph H.
Simhadri, Vijaya
Adolf-Bryfogle, Jared
Khare, Sagar D.
Dunbrack, Roland L.
Gray, Jeffrey J.
Sauna, Zuben E.
author_facet Hernandez, Nancy E.
Jankowski, Wojciech
Frick, Rahel
Kelow, Simon P.
Lubin, Joseph H.
Simhadri, Vijaya
Adolf-Bryfogle, Jared
Khare, Sagar D.
Dunbrack, Roland L.
Gray, Jeffrey J.
Sauna, Zuben E.
author_sort Hernandez, Nancy E.
collection PubMed
description
format Online
Article
Text
id pubmed-10493423
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104934232023-09-12 Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032] Hernandez, Nancy E. Jankowski, Wojciech Frick, Rahel Kelow, Simon P. Lubin, Joseph H. Simhadri, Vijaya Adolf-Bryfogle, Jared Khare, Sagar D. Dunbrack, Roland L. Gray, Jeffrey J. Sauna, Zuben E. Heliyon Corrigendum Elsevier 2023-07-06 /pmc/articles/PMC10493423/ /pubmed/37701412 http://dx.doi.org/10.1016/j.heliyon.2023.e17901 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Corrigendum
Hernandez, Nancy E.
Jankowski, Wojciech
Frick, Rahel
Kelow, Simon P.
Lubin, Joseph H.
Simhadri, Vijaya
Adolf-Bryfogle, Jared
Khare, Sagar D.
Dunbrack, Roland L.
Gray, Jeffrey J.
Sauna, Zuben E.
Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title_full Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title_fullStr Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title_full_unstemmed Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title_short Corrigendum to “Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus” [Heliyon 9(4) (April 2023) e15032]
title_sort corrigendum to “computational design of nanomolar-binding antibodies specific to multiple sars-cov-2 variants by engineering a specificity switch of antibody 80r using rosettaantibodydesign (rabd) results in potential generalizable therapeutic antibodies for novel sars-cov-2 virus” [heliyon 9(4) (april 2023) e15032]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493423/
https://www.ncbi.nlm.nih.gov/pubmed/37701412
http://dx.doi.org/10.1016/j.heliyon.2023.e17901
work_keys_str_mv AT hernandeznancye corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT jankowskiwojciech corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT frickrahel corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT kelowsimonp corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT lubinjosephh corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT simhadrivijaya corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT adolfbryfoglejared corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT kharesagard corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT dunbrackrolandl corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT grayjeffreyj corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april
AT saunazubene corrigendumtocomputationaldesignofnanomolarbindingantibodiesspecifictomultiplesarscov2variantsbyengineeringaspecificityswitchofantibody80rusingrosettaantibodydesignrabdresultsinpotentialgeneralizabletherapeuticantibodiesfornovelsarscov2virusheliyon94april

Ejemplares similares